Emerging Role of Immunogenic Cell Death in Cancer Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 4242
Special Issue Editor
2. Center for Advanced Studies and Technology (CAST), 66100 Chieti, Italy
Interests: targeted therapy; tumor biology; monoclonal antibody; antibody drug conjugate; extracellular vesicles
Special Issue Information
Dear Colleagues,
In the past few years, the concept of immunogenic cell death (ICD) has emerged, which underlines the important role of the immune system in the efficacy of cancer therapy. Indeed, several studies have demonstrated that cancer cell lines treated ex vivo with anthracyclines, oxaliplatin, photodynamic therapy (PDT) or γ-irradiation and are then implanted subcutaneously into syngeneic immuno-competent mice function as a cancer vaccine in the absence of any adjuvants or immunostimulatory substances by protecting mice against subsequent rechallenges with live cancer cell lines.
Immunogenic cell death (ICD) is a form of regulated cell death accompanied by the exposure, active secretion, or passive release of numerous DAMPs (damage-associated molecular patterns) that can function as either adjuvants or danger signals in the activation of both innate and adaptive immune responses. ICD can be induced by different stressors, including (1) intracellular pathogens; (2) certain chemotherapeutic drugs such as anthracyclines, DNA-damaging agents, and proteasomal inhibitors; (3) oncolytic viruses; (4) targeted anticancer agents such as the tyrosine kinase inhibitor crizotinib, the epidermal growth factor receptor-specific monoclonal antibody cetuximab, and poly-ADP-ribose polymerase (PARP) inhibitors; (5) physicochemical therapies and photodynamic therapy; and (6) radiotherapy. So, there is evidence that treatment-driven ICD can elicit anticancer immune responses that reinforce the therapeutic effects of conventional anti-cancer chemotherapies and radiotherapy.
This Special issue aims at expanding the current knowledge on ICD-related processes and molecules, on ICD inducers, and on the underlying mechanisms of signaling mediated by DAMPs in order to improve cancer therapies in a personalized, biomarker-driven manner. Experimental studies using in vitro and in vivo models, review articles, and clinical studies are all also welcome for consideration.
Dr. Emily Capone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunogenic cell death
- adaptive immune response
- DAMPs
- cell death
- cancer therapy
